Diagnosis and treatment of hypothalamic-pituitary-adrenal (HPA) axis dysfunction in patients with chronic fatigue syndrome (CFS) and fibromyalgia (FM)

Journal of Chronic Fatigue Syndrome

Volumn 14, Issue 3, 2008, Pages 59-88

  Holtorf, Kent ^a,b  

^a Holtorf Medical Group Inc   (United States)

^b Fibromyalgia and Fatigue Centers Inc   (United States)

Author keywords

CFIDS; Chronic fatigue syndrome; Cortisol; Fibromyalgia; HPA axis dysfunction; Hydrocortisone; Hypothalamic pituitary adrenal axis

Indexed keywords

CORTICOTROPIN; DEXFENFLURAMINE; DULOXETINE; FLUDROCORTISONE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; IPSAPIRONE; METYRAPONE; PLACEBO;

ABBREVIATED FATIGUE QUESTIONNAIRE; ADRENAL SUPPRESSION; ARTICLE; BLOOD PRESSURE; CHRONIC FATIGUE SYNDROME; CORTICOSTEROID THERAPY; CORTICOTROPIN TEST; DRUG WITHDRAWAL; FIBROMYALGIA; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INCIDENCE; INDIGESTION; LABORATORY TEST; LOW DRUG DOSE; MASS SPECTROMETRY; OSTEOLYSIS; POSTTRAUMATIC STRESS DISORDER; QUESTIONNAIRE; RASH; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 39749108072     PISSN: 10573321     EISSN: 15470660     Source Type: Journal    
DOI: 10.1300/J092v14n03_06     Document Type: Article

References (179)

1. Wolfe F et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995 Jan;38(1):19-28.
2. Topbas M et al. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol. 2005 Mar-Apr;34(2):140-4.
3. Neumann L, Buskila D. Epidemiology of Fibromyalgia. Current Pain and Headache Reports 2003, 7:362-8.
4. Wearden AJ, Morriss RK, Mullis R, et al. Randomized, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome [published erratum appears in Br J Psychiatry 1998;173:89]. Br J Psychiatry 1998. 172:485-90.
5. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. The Lancet 1996; 347:858-61.
6. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15.
7. Barclay L, Vega C. Duloxetine Effective in Fibromyalgia. Medscape Medical News. Sept 10, 2004.
8. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997 Sep;40(9):1571-9.
9. Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome patients at diagnosis and 5-year follow-up. Journal of Psychosomatic Research 2004;56:217-29.
10. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue syndrome: a systematic review. Q J Med 1997;90(3):223-33.
11. Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs. JAMA. Vol. 276 No. 18, November 13, 1996.
12. Levine PH et al. The Postinfectious Chronic Fatigue Syndrome. Humana Press, Clifton, NJ 1989:405-38.
13. Deale A, Wessely S. Patients' perceptions of medical care in chronic fatigue syndrome. Social Science & Medicine 2001;52:1859-64.
14. Hinds GME, McCluskey DR. A retrospective study of chronic fatigue syndrome. Proc Roy Coll Physicians, Edinburgh 1993; 23:10-14.
15. Peterson PK, Schenck CH, Sherman R. Chronic fatigue syndrome in Minnesota. Minnesota Medicine 1991;74:21-6. Pain 1995;3:91-110.
16. Bennett RM: Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum 1996;39:1627-34.
17. Kennedy M, Felson DT. A prospective long-term study of fibromyalgia syndrome. Arthritis Rheum. 1996;39(4):682-5.
18. Wilson A et al. The treatment of chronic fatigue syndrome: science and speculation. Am J Med 1994;96(6):544-50.
19. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJP et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-34.
20. Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998;97(6):450-7.
21. Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol Psychiatry 1999;45(11):1447-54.
22. Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V. Hypothalamo-pituitary-adrenal axis function in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001;86:3545-54.
23. Inder WJ,, Prickett TC, Mulder RT. Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment. Clinical Endocrinology 2005;62:343-8.
24. Gaab J, Huster D, Peisen R, Engert V, Heitz V, Schad T, Schurmeyer TH, Ehlert U. Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation. Psychosom Med 2002;64(6):951-62.
25. Bearn J, Allain T, Coskeran P, Munro N, Butler J, McGregor A, Wessely S Neuroendocrine responses to D-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biol Psychiatry 1995;37:245-52.
26. Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P. Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 1997;22:261-7.
27. Riedel W, Layka H, Neeck. Secretory pattern of GH, TSH, thryoid hormones, ACTH, cortil, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998; 57:81-7.
28. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469-74.
29. Griep EN, Boersma JW, Lentjes, Lentjes EG, Prins JK. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998;25(7):1374-81.
30. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37(11):1583-92.
31. Calis M, Gokce C. Investigation of the hypothalamo-pituitary-adreanl axis (HPA) by 1ug ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. J Endocrinol Invest 2004;27:42-6.
32. Torpy DJ et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6 in fibromyalgia. Arthritis and Rheumatism. 2000;43:872-80.
33. Adler GK, Kinsley BT, Hurwitz S, Mossey C, Goldenberg DL. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999;106:534-43.
34. Torpy DJ, Chrousos GP. The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. B. Clinical Rheumatology 1996;10(2):181-98.
35. Scott LV, Medbak S, Dinan TG. The low dose ACTH test in chronic fatigue syndrome and in health. Clin Endocrinol (Oxf) 1998;48(6):733-7.
36. Soule S et al. The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism. Clinical Endocrinology 2000;53:221.
37. Fiad TM, Kirby JM, Cunningham SK, McKenna TJ. The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary- adrenal axis. Clin Endocrinol (Oxf) 1994;40(5):603-9.
38. Cunningham SK, Moore A, McKenna TJ. Normal cortisol response to corticotropin in patients with secondary adrenal failure. Arch Int Med 1983;143(12):2276-9.
39. Mayenknecht J et al. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. The Journal of Clinical Endocrinology & Metabolism 1998; 83(5):1558-62.
40. Kirnap M, Colak R, Eser C, Ozsoy O, Tutus A, Kelestimur F. A comparison between low-dose (1 microg), standard-dose (250 microg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitary-adrenal axis in primary fibromyalgia syndrome. Clin Endocrinol (Oxf) 2001;55(4):455-9.
41. Scott LV, Medbak S, Dinan TG. The low dose ACTH test in chronic fatigue syndrome and in health. Clin Endocrinol (Oxf) 1998;48:733-7.
42. Tordjman K, Jaffe A, Grazas N, Apter C, Stern N. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. Journal of Clinical Endocrinology & Metabolism 1995;80:1301-5.
43. Oelkers W. The role of high- and low-dose corticotropin tests diagnosis of secondary adrenal insufficiency. European Journal of Endocrinology 1998;139:567-70.
44. Zarkovic M, Ciric J, Stojanovic M, et al. Optimizing the diagnostic criteria for standard (250-mg) and low dose (1-mg) adrenocorticotropin tests in the assessment of adrenal function. J Clin Endocrinol Metab 1999;84:3170-3.
45. Demitrack M, Dale J, Straus S, Laue L, Listwak S, Kruesi M, Chrousos G, Gold P. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-34.
46. Scott LV, Dinan TG. Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. Journal of Affective Disorders 1998;47:49-54.
47. Cleare AJ, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fatigue syndrome. Am J Psychiatry 2001;158:641-3.
48. Young et al. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome. Boil Psychiatry 1998;43:236-7.
49. Maes M, Lin A, Bonaccorso S, Van Hunsel F, Van Gastel A, Delmeire L, Biondi M, Bosmans E, Kenis G, Scharpe S. Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998;98(4):328-35.
50. De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, Smitz J, Velkeniers B. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res 1999;31(1):18-21.
51. Crofford L. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. J Rheumatol 1998;57 Suppl 2:67-71.
52. Kuratsune H, Yamaguti K, Sawada M, Kodate S, Machii T, Kanakura Y, Kitani T. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. Int J Mol Med 1998;1(1):143-6.
53. Strickland P, Morris R, Wearden A, Deakin B. A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. J Affect Disord 1998;47(1-3):191-4.
54. Jefferies W. Mild adrenocortical deficiency, chronic allergies, autoimmune disorders and the chronic fatigue syndrome: a continuation of the cortisone story. Med Hypotheses 1994;3(42):183-9.
55. Cleare AJ, Bearn J, Allain T, McGregor A, Wessely S, Murray RM, O'Keane V. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord, 1995;18(4):283-9.
56. Moutschen M, Triffaux JM, Demonty J, Legros JJ, Lefèbvre PJ. Pathogenic tracks in fatigue syndromes. Acta Clin Belg 1994;6(49): 274-89.
57. Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 1998;840:684-97.
58. McLean SA et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis & Rheumatism 2005;52(11):3660-9.
59. Neeck G, Riedel. Thyroid Function in Patients with Fibromyalgia Syndrome. J Rheumatology 1992;19(7):1120-2.
60. Neeck G, Riedel W. Hormonal perturbations in fibromyalgia syndrome. Annals New York Academy of Sciences 1999;876:325-39.
61. Simons DG, Travell JG. Myofacial pain syndromes, perpetuation factors. In Textbook of Pain. P.D. Wall & R. Malzak, Eds.1989:369-85.
62. McCain GA, Tilbe AK. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol 1989;16(Supp19):154-7.
63. Ferraccioli G, Cavalieri F, Salaffi F, Fontana S, Scita F, Nolli M, Maestri D. Neuroendocrinologic findings in primary fibromyalgia and in other rheumatic conditions. J. Rheumatol 1990;17:869-73.
64. Englebienne P, Verhas M, Herst CV, Ke Meirleir K. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue. Med Hypoth 2003;60(2):175-80.
65. Garrison RL, Breeding PC. A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. Medical Hypoth 2003;61(2):182-9.
66. Cullum ME et al. Mutations in the c-erbAB1 gene: do they underlie euthyroid fibromyalgia. Medical Hypotheses 1997;48:125-35.
67. Lowe JC. Thyroid status of 38 Fibromyalgia Patients: Implications for the etiology of fibromyalgia. Clin Bulletin Myofascial Therapy 1997;2(1):47-64.
68. Lowe JC, Reichman AJ, Honeyman GS, Yellin J. Thyroid status of fibromyalgia patients. Clin Bulletin Myofascial Therapy 1998;3(1):69-70.
69. Lowe JC. The Metabolic Treatment of Fibromyalgia. Ed., Yelin JC. McDowell Publishing Company 2000.
70. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with fibromyalgia syndrome. A possible link between sleep and muscle pain. Arthritis and Rheumatism 1992;35(10):1110-13.
71. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol. 1997; 24:1384-9.
72. Bennett R. Growth hormone in musculoskeletal pain states. Current Pain and Headache Reports 2005;9:331-8.
73. Bennett RM. Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol 1998;57(Supp 2):72-6.
74. Bennett RM, Clark SR, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31.
75. Behan WM. Muscles, mitochondria and myalgia. J Pathology 1992;166:213-14.
76. Riley MS, O'Brien CJ, McCluskey DR et al. Aerobic work capacity in patients with chronic fatigue syndrome. Brit Med J 1990;301:953-6.
77. Behen WH, More IR, Behan PO. Mitochondrial abnormalities in postviral fatigue syndrome. Acta Neuropathol 1991;83:61-5.
78. Nicolson G, Ellithorpe R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. Journal of Chronic Fatigue Syndrome 2006;13(1):57-68.
79. Pillemer S, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of FMS-[An NIH] conference summary. Arthritis & Rheumatism 1997;40 (11):1928-39.
80. Drewes AM, Nielson KD, Taagholt SJ, Bjerregaard K, Svendson L, Gade J. Slow wave sleep in FMS. J Musculoskeletal Pain 1995;3(Supp1):29.
81. Scharf MB, Baumann M, Berkowitz D. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatology 2003;30:1070-4.
82. Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986;81:85-9.
83. Moldofsky H. Sleep and fibrositis syndrome. Rheum Dis Clin North Am 1989;15:91-103.
84. Moldofsky H. The contribution of sleep-wake physiology to fibromyalgia. Adv Pain Res Ther 1990;17:227-40.
85. Klimas NG et al. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiology 1990;28(6):1403-10.
86. Peterson A, Komaroff L, and Ritz J. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987;139:3306-13.
87. Fletcher MA, Maher KJ, Klimas NG. Natural killer cell function in chronic fatigue syndrome 2002;2(2):129-39.
88. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994;18(Supp 1):S157-9.
89. Komaroff A. The biology of chronic fatigue syndorme. Am J Med 2000;108:169-71.
90. Vojdani et al. RNase L in health and disease: what did we learn recently? Journal of Chronic Fatigue Syndrome 2003;11(2):97-109.
91. Suhadolnik RJ et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I) poly(C12U) in chronic fatigue syndrome. In Vivo. 1994;8:599-604.
92. Suhadolnik RJ et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994;18:S96-S104.
93. Suhadolnik RJ et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon & Cytokine Res1997;17:377-85.
94. Suhadolnik RJ et al. Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome. J Chronic Fatigue Syndrome. 1999;5:223-42.
95. De Meirleir K et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000;108(2):99-105.
96. Zorenzenon M, Rukh G Botta GA et al. Active HHV-6 infection in chronic fatigue syndrome patients from Italy: new data. J Chronic Fatigue Syndrome 1996;2(4):3-12.
97. Jo Nijs J et al. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunology & Medical Microbiology 2002;34: 209-14.
98. Nicolson G, Nicolson N. Diagnosis and treatment of Mycoplasmal infections in Persian Gulf War Illness-CFIDS patients. International Journal of Occupational Medicine, Immunology and Toxicology 1996;5:69-78.
99. Knox KK, Brewer JH, Carrigan DR. Persistent active human herpesvirus six (HHV-6) infections in patients with chronic fatigue syndrome. J Chronic Fatigue Syndrome 1999;5:245-6.
100. Brewer JH, Know KK and Carrigan DR. Longitudinal study of chronic active human herpesvirus 6 (HHV-6) viremia in patients with chronic fatigue syndrome. Abstract. IDSA 37th Annual Meeting. Nov. 18-21, 1999. Philadelphia, Pennsylvania.
101. Ablashi DV et al. Human herpes virus and chronic fatigue syndrome. Canad Dis Weekly Rep 1991;17S1:33-40.
102. Josephs SF et al. HHV-6 reactivation in chronic fatigue syndrome. Lancet 1991;1346-7.
103. Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS 2003;111(5):557-66.
104. Buchwald D. et al. A chronic illness characterized by fatigue, neurological and immunological disorders, and active human herpesvirus type 6 infection. Annals of Internal Medicine 1992;116:103-13.
105. Martin WJ. Detection of viral related sequences in CFS patients using the polymerase chain reaction. In "The Clinical and Scientific Basis of Myalgic Encephalomyelitis Chronic Fatigue Syndrome." Byron M. Hyde Editor. Nightingale Research Foundation Press. Ottawa, Canada, pp. 278-83, 1992.
106. Rowe PC, Bou-Holaigah I, Kan JS, Calkins H. Is NMH an unrecognized cause of chronic fatigue? Lancet 1995;345:623-4.
107. Naschitz JE, Rosner I, Rozenboum M et al. The head-up tilt test with haemo dynamic instability score in diagnosing chronic fatigue syndrome. QJ Med 2003;96:133-42.
108. Gerrity TR, Bates J, Bell DS, Chrousos G, Furst G, Hedrick T, Hurwitz B, Kula RW, Levine SM, Moore RC, Schondorf R. Chronic fatigue syndrome: what role does the autonomic nervous system play in the pathophysiology of this complex illness? NeuroImmunoModulation 2002;10:134-41.
109. Wallace DJ, Gallegua DS. Fibromyalgia: the gastrointestinal link. Current Pain and Headache Reports 2004;8:364-8.
110. Sivri A, Cindas A, Dincer F, Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Clin Rheumatol 1996;15(3):283-6.
111. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci 1991;36(1):59-64.
112. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Annals of the Rheumatic Diseases 2004;63:450-2.
113. Mark Pimentel et al. Small intestinal bacterial overgrowth: a possible association with fibromyalgia. Journal of Musculoskeletal Pain 2001;9(3):107-13.
114. Berg D, Berg LH, Couvaras J, Harrison H. Chronic Fatigue Syndrome (CFS) &/or Fibromyalgia (FM) as a Variation of Antiphospholipid Antibody Syndrome (APS): An Explanatory Model and Approach to Laboratory Diagnosis of Blood Coagulation and Fibrinolysis 1999;10:1-4.
115. Berg D, Berg LH, Couvaras J. Is CFS/FM due to an undefined hypercoaguable state brought on by immune activation of coagulation. Does adding anticoagulant therapy improve CFS/FM patient symptoms? AACFS Proceedings, Cambridge, MA, 10-12 October1998:62.
116. Berg D, Berg LH, Harrison H, Dreschsel. Retrospective study of 400+ CFS/FM patients for immune system activation of coagulation and hereditary coagulation defects as predisposition for CFS/FM. Proceedings International Society Thrombosis & Hemostasis July, 2001.
117. Harrison H, Ryser CA, , Brewer J, Berg D. Procoagulant Genetic Factors in a Pooled Cohort of 582 Chronic Fatigue Syndrome, Fibromyalgia and Related Chronic Illness Cases. VIIth International Conference American Association for Chronic Fatigue Syndrome (AACFS), Oct, 2004, Madison, WI, USA
118. Berg D, Berg LH, Harrison H. Low Level Activation of Coagulation with Coagulopathies in the Etiology of CFS / FM and Chronic Illnesses. An Explanatory Model Revisited. VIIth International Conference, American Association for Chronic Fatigue Syndrome (AACFS) Meeting, Madison, WI, Oct, 2004.
119. Harrison HH, Ryser CA, Ryser ME, et al. Use of sensitive markers of coagulation activation to monitor low dose heparin therapy in patients with CFS and FM. Clinical Chemistry 2003;49(S6):A9.
120. Teitelbaum J, Bird B, Greenfield R, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome (CFIDS) & fibromyalgia (FMS) - A randomized, double-blind, placebo-controlled, intent to treat study. Journal of Chronic Fatigue Syndrome 2001;8(2):3-28.
121. Blatman H. Effective Treatment of fibromyalgia and myofascial pain syndrome: a clinician's perspective. American Journal of Pain Management (Journal of the American Academy of Pain Management) 2002;12(2):67-8.
122. American Academy of Environmental Medicine 38th Annual Meeting, Identifying the Cause and Exploring the Newest Treatment Option for Chronic Fatigue Syndrome, Fibromyalgia and Environmental Sensitivities, Phoenix, AZ, Oct 30-Nov 2, 2003.
123. De Meirleir K, Englebienne P. Chronic Fatigue Syndrome: A Biological Approach. CRC Press. 2002.
124. Teitelbaum J. Effective treatment of chronic fatigue syndrome: clinical protocols and practice. Integrative Medicine 2005;4(4):CD-CG.
125. International Association for Chronic Fatigue Syndrome (IACFS), Centers for Disease Control and Prevention (CDC) and the National Center for Infectious Diseases. Seventh International Conference on Chronic Fatigue Syndrome, Fibromyalgia and Other Related Illnesses. October 8-10, Madison, Wisconsin 2004.
126. International Association for Chronic Fatigue Syndrome (IACFS), Centers for Disease Control and Prevention (CDC) and PANDORA. Eighth International Conference on Chronic Fatigue Syndrome, Fibromyalgia and Other Related Illnesses. Fort Lauderdale, FL, Jan 12-14, 2007.
127. Effective Treatment of Chronic Fatigue Syndrome, Pain and Fibromyalgia - A Double-blind Study. The 12th Annual World Congress on Anti-Aging Medicine, Las Vegas, NV 2005.
128. Latest 21st Century Advances in the Diagnosis & Treatment of Fibromyalgia, Chronic Fatigue Syndrome and Related Illnesses. Los Angeles, CA, Sept 19-21, 2002.
129. Ali M et al. Efficacy of ecologic-integrative management; protocols for reversal of fibromyalgia. J Integrative Medicine 1999;3:48-64.
130. Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. Clinical Bulletin of Myofascial Therapy 1997;2(2/3):91-124.
131. PreAmerican Association for CFS/FMS 7th International Conference. A clinically focused workshop on Effective CFS/Fibromyalgia Therapies. October 7, 2004 Madison, Wisconsin.
132. Potential Unique etiologies of Chronic Fatigue Syndrome and Fibromyalgia: Hypercoaguable State, Neurotoxins & Heavy Metals. Fifth Annual Fibromyalgia and Chronic Fatigue Conference. Kansas City, MO. Fibromyalgia Coalition International May 14, 2005.
133. Hormone Replacement Therapy in the Treatment of Fibromyalgia and CFIDS/ Fibromyalgia CME Conference National Fibromyalgia Association. Garden Grove, CA. May 18, 2006.
134. The Treatment of the Metabolic Consequences of CFS/FM and Chronic Infections. American College for the Advancement of Medicine. Dallas, TX. May 4, 2006.
135. Teitelbaum J. From Fatigue to Fantastic. Penguin Putnam Inc., 2001.
136. Holtorf K, Wightman W, Tenenbaum S, Shah P, White MD. Outcome database of 500+ CFS/FM patients. Holtorf Medical Group Inc., Center for Hormone Imbalance, Hypothyroidism and Fatigue, Torrance, CA 2007.
137. Holtorf K, Wightman W, Tenenbaum S, Shah P, White MD, Spurlock M, Kippels K, LaBair A, Sharp L, Pierotti A, Bullington K, Garcia A, Stevens J, Sainer D, Campo A, Garabedian A, Marti L, Taveau S, Cuddapah S, Mustafa S, Stringer B, Boulden K, Bial E, Truong B, Elzinga L, Wazni G, Whitaker J, Cuddapah S, Lipschutz S, Stringer DiGiovanni M, Levitz L, Hamp D, Juguilon F, Calabrese D, Zahoor I, Nurse-Bey H, Sidhwa Y, Shanti I, Littles C, Kelly L. Outcome database of 5000+ CFS/ FM patients. Dallas TX, Fort Worth TX, Las Vegas NV, Salt Lake City UT, Portland OR, Seattle WA, Atlanta GA, Norwalk CT, Boston MA, Philadelphia PA, Cleveland OH, Denver CO, Houston, TX, Detroit MI, Pittsburgh PA, Amarillo TX, Houston TX.
138. Lowe J, Garrison R, Reichman A, MD, Yellin J, Thompson BA, Kaufman D. Effectiveness and safety of T3 (triiodothyronine) therapy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study. Clinical Bulletin of Myofascial Therapy 1997;2(2/3):31-58.
139. Lowe JC, Reichman AJ, Garrison R, Yellin J. Triiodothyronine (T3) treatment of euthyroid fibromyalgia: a small-n replication of a double-blind placebo-controlled crossover study. Clinical Bulletin of Myofascial Therapy 1997;2(4):71-88.
140. Yellin BA, Reichman AJ, Lowe JC. The Process of Change During T3 Treatment for Euthyroid Fibromyalgia: A Double-Blind Placebo-Controlled Crossover Study. The Metabolic Treatment of Fibromyalgia. McDowell Publishing 2000.
141. Moorkens G, Wynants H, Abs R. Effect of growth hormone treatment in patients with chronic fatigue syndrome: a preliminary study. Growth Horm IGF Res 1998;8(B):131-3.
142. Nicolson G, Marwan Y, Nasralla M, De Meirleir K, Haier J. Bacterial and Viral Co-Infections in Chronic Fatigue Syndrome (CFS/ME) Patients. Proc. Clinical & Scientific Conference on Myalgic Encephalopathy/Chronic Fatigue Syndrome, the Practitioners Challenge, Alison Hunter Foundation, Sydney, Australia 2002.
143. Lerner AM, Zervos M and Chang CH et al. A small, randomized, placebo-controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. Clinical Infectious Diseases 2001;32:1657-8.
144. Nicolson GL, Nasralla MY, Franco RA, Nicolson NL, Erwin R, Ngwenya R, Berns PA. Clinical Practice of Alternative Medicine 2000; 1(2):92-102.
145. Montoya et al. Use of valganciclovir (Valcyte) in patients with elevated anti-body titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. Journal of Clinical Virology 2006;37:S33-38.
146. Cleare AJ et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomized crossover trial. Lancet 1999;353(9151):455.
147. Cohen J, Ward G, Prins J, Jones M, Venkatesh B. Variability of cortisol assays can confound the diagnosis of adrenal insufficiency in the critically ill population. Intensive Care Med 2006;32(11):1901-5.
148. Nye EJ, Grice JE, Hockings Gi, Strakosch CR, Crosbie GV, Walters MM, Jackson RV. Comparison of adrenocorticotropin (ACTH) stimulation tests and insulin hypoglycemia in normal humans: low dose, standard high dose, and 8-hour ACTH-(1-24) infusion tests. Journal of Clinical Endocrinology & Metabolism 1999;84(10):3648-3655.
149. De Brabandere VI, Thienpont LM, Stockl D, De Leenheer AP. Three routine methods for serum cortisol evaluated by comparison with an isotope dilution gas chromatography-mass spectrometry method. Clin Chem 1995;41(12 Pt 1):1781-3.
150. Clark, Neylon, Raggatt, Sheppard, Stewart. Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clinical Endocrinology 1998;49(3):287-92.
151. Briegel J, Vogeser M, Annane D, Singer M, Keh D, Moreno R, Sprung C. Correct identification of relative adrenal insufficiency in septic shock. Intensive Care Med 2005;Suppl 1:S160.
152. Dorin RI, Qualls RC, Crapo LM. Diagnosis of adrenal insufficiency. Annals of Internal Medicine 2003;139(3):194-204.
153. Blockmans D, Persoons P, Van Houdenhove B, et al. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. Am J Med 2003;114:736-41.
154. McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, Garcia-Borreguero D, Blackwelder W, Straus SE. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998;280(12):1061-6.
155. Jefferies W. Cortisol and immunity. Medical Hypotheses 1991;34:198-208.
156. Teitelbaum et al. Low-dose hydrocortisone for chronic fatigue syndrome. JAMA 1999;281(20);1887-8.
157. Jefferies WM. Safe Uses of Cortisol. 2nd ed. Charles C. Thomas, 1996.
158. Investigations of hydrocortisone and fludrocortisone in the treatment of chronic fatigue syndrome. The Journal of Clinical Endocrinology & Metabolism 1999;84(6):2263-4.
159. Dessein P, Shipton E. Hydrocortisone and chronic fatigue syndrome. The Lancet 1999;353:1618.
160. Baschetti R. Hydrocortisone and chronic fatigue syndrome. The Lancet 1999;353:1618.
161. Baschetti R. Low-dose hydrocortisone for chronic fatigue syndrome. JAMA 1999;281(20):1887.
162. Teitelbaum JE. Hydrocortisone and chronic fatigue syndrome. The Lancet 1999;353:1618-1619.
163. Cho et al. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. Psychosom Med 2005;67:301-13.
164. Katz P, Zaytoun AM, Lee JH. The effects of I vivo hydrocortisone on lymphocyte-mediated cytotoxicity. Arthritis Rheum 1984;27(1):72-8.
165. Kronfol A et al. Circadian immune measures in healthy volunteers: Relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. Psychosomatic Medicine 1997;59:42-50.
166. Tuchenda M, Newcomb RW, DeVald BL. Effect of prednisone treatment on the human immune response to keyhole limpet hemocyanin. Int Arch Allergy 1972;42:533.
167. Rusu UM, Cooper MD. In vivo effects of cortisone on the B cell line in chickens. J Immunol 1975;115:1370.
168. Fauci AS, Pratt KR, Whalen G. Activation of human B lymphocytes. IV. Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes in polyclonal activation. J Immunol 1977;119:598.
169. Orson FM, Grayson J, Pike S, DeSeau V, Blaese RM. T cell-replacing factor for glucocorticosteroid-induced immunoglobulin production. A unique steroid-dependent cytokine. J Exp Med 1983;158:1473.
170. Orson FM, DeSeau V, Pike S, Blaese M. Glucocorticosteroids stimulate polyclonal immunoglobulin production by cord blood mononuclear cells. J Immunol 1984;133:208.
171. Levo Y, Harbeck RJ, Kirkpatrick CH. Regulatory effect of hydrocortisone on the in vitro synthesis of IgE by human lymphocytes. Int Archs Allergy Appl Immun 1985;77: 413.
172. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Di. 2006;65(3):285-93.
173. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333:142-6.
174. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council
175. Rau R, Wassenberg S, Zeidler H. Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis-preliminary results of a multicenter, randomized, parallel, double blind study. Z Rheumatol 2000;59(Supp 2):II/90-II/96.
176. Van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
177. Manji RJ et al. Depression of cell-mediated immunity during acute infectious mononucleosis. N Engl J Med 1974;291:1149.
178. Dafny N et al. Lateral hypothalamus: site involved in pain modulation. Neuroscience 1996;70(2):449-460.
179. Kalsbeek A, Van Heerikhuize J, Wortel J, RBuijs RM. A diurnal rhythm of stimulatory input to the hypothalamo-pituitary-adrenal system as revealed by timed intrahypothalamic administration of the vasopressin V1 antagonist. The Journal of Neuroscience 1996;16(17):5555-65.